中棘神经元
神经科学
多巴胺
纹状体
直接运动途径
谷氨酸受体
多巴胺受体D2
兴奋性突触后电位
谷氨酸的
生物
突触后电位
受体
抑制性突触后电位
生物化学
作者
Daisy L. Spark,Miaomiao Mao,Sherie Ma,Mohsin Sarwar,Cameron J. Nowell,David M. Shackleford,Patrick Michael Sexton,Jess Nithianantharajah,Gregory D. Stewart,Christopher J. Langmead
标识
DOI:10.1021/acschemneuro.0c00197
摘要
GPR52 is a Gα s -coupled orphan receptor identified as a putative target for the treatment of schizophrenia. The unique expression and signaling profile of GPR52 in key areas of dopamine and glutamate dysregulation suggests its activation may resolve both cortical and striatal dysfunction in the disorder. GPR52 mRNA is enriched in the striatum, almost exclusively on dopamine D 2 -expressing medium spiny neurons (MSNs), and to a lesser extent in the cortex, predominantly on D 1 -expressing pyramidal neurons. Synthetic, small molecule GPR52 agonists are effective in preclinical models of psychosis; however, the relative contribution of cortical and striatal GPR52 is unknown. Here we show that the GPR52 agonist, 3-BTBZ, inhibits phencyclidine-induced hyperlocomotor activity to a greater degree than amphetamine-induced motor effects, suggesting a mechanism beyond functional antagonism of striatal dopamine D 2 receptor signaling. Using DARPP-32 phosphorylation and electrophysiological recordings in either striatopallidal or striatonigral MSNs, we were surprised to find no significant effect of 3-BTBZ in striatopallidal MSNs, but GPR52-mediated effects in striatonigral MSNs, where its mRNA is absent. 3-BTBZ increases phosphorylation of T75 on DARPP-32 in striatonigral MSNs, an effect that was dependent on cortical inputs. A similar role for GPR52 in regulating extrastriatal glutamatergic drive onto striatonigral MSNs was also evident in recordings of spontaneous excitatory postsynaptic currents and was shown to be dependent on the metabotropic glutamate (mGlu) receptor subtype 1. Our results demonstrate that GPR52-mediated regulation of striatal function depends heavily on extrastriatal inputs, which may further support its utility as a novel target for the treatment of schizophrenia.
科研通智能强力驱动
Strongly Powered by AbleSci AI